Clinical Trials · NCT07262762
Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
- Phase
- N/A
- Recruitment status
- Recruiting
- Sponsor
- Cinnagen
- Enrollment
- 175
- Start date
- Nov 2025
- Locations
- 14 sites, Iran
- Primary endpoint
- Proportion of patients with ≥5% weight loss